Advances in meningioma genomics, proteomics, and epigenetics: insights into biomarker identification and targeted therapies

Ahmad A. Nazem; Jacob Ruzevick; Manuel J. Ferreira Jr

doi:10.18632/oncotarget.27841

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Perspectives:

Advances in meningioma genomics, proteomics, and epigenetics: insights into biomarker identification and targeted therapies

Ahmad A. Nazem, Jacob Ruzevick and Manuel J. Ferreira Jr _

PDF | Full Text | How to cite

Oncotarget. 2020; 11:4544-4553. https://doi.org/10.18632/oncotarget.27841

Metrics: PDF 1286 views | Full Text 2557 views | ?

Abstract

Ahmad A. Nazem1^,*, Jacob Ruzevick1^,* and Manuel J. Ferreira Jr1

1 Department of Neurosurgery, University of Washington School of Medicine, University of Washington Medical Center, Seattle, WA, 98195, USA

* These authors contributed equally to this work

Correspondence to:

Manuel J. Ferreira Jr,

email:

[email protected]

Keywords: meningioma; skull base; NGS; sequencing; biomarker

Received: October 21, 2020 Accepted: November 03, 2020 Published: December 08, 2020

Copyright: © 2020 Nazem et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Meningiomas are a heterogeneous group of tumors, defined histo-pathologically by World Health Organization (WHO) grading. The WHO grade of meningiomas does not always correlate with clinical aggressiveness. Despite maximal surgical resection and adjuvant radiation, a subset of tumors are clinically aggressive; displaying early recurrence and invasion. Current methods for identifying aggressive meningiomas solely focus on genomics, proteomics, or epigenetics and not a combination of all for developing a real-time clinical biomarker. Improved methods for the identification of these outlying tumors can facilitate better classification and potentially adjuvant treatment planning. Understanding the pathways of oncogenesis using multiple markers driving aggressive meningiomas can provide a foundation for targeted therapies, which currently do not exist.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 27841

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Perspectives:

Advances in meningioma genomics, proteomics, and epigenetics: insights into biomarker identification and targeted therapies

Abstract